Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
The revised guidance is primarily related to the performance of Merck's coxib franchise in overseas markets. A potential fourth quarter U.S. launch of Arcoxia is not included in the guidance.
You may also be interested in...
Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication
FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.
Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.
Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication
FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: